5 completed, 4 recruiting, 3 not yet recruiting, 2 unknown. 6 Phase 4, 3 Phase 3, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 3, Not yet recruiting 2, Recruiting 1 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Tinea Corporis: new trials by email Literature Review of Tinea Corporis trials Research Report on Tinea Corporis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in Dermatophytosis Itraconazole, Luliconazole Cream 1%, Bifonazole cream 1% - Tinea Corporis, Tinea Cruris | Phase 4 | Not yet recruiting | University of Faisalabad | 182 | 2026-12-01 | 2026-11-12 |
| In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan In vitro antifungal susceptibility testing - Dermatophytosis, Tinea Corporis | Recruiting | Dr. Amara Safdar | 120 | 2026-10-02 | 2026-10-27 | |
| Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis/ Cruris-A Randomised Controlled Trail Itraconazole (200 mg), ISOtretinoin 20 MG - Tinea Corporis | Phase 4 | Not yet recruiting | Pak Emirates Military Hospital | 60 | 2026-10-01 | 2026-06-30 |
| Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis Direct microscopic KOH examination, Culture:, Antifungal susceptibility testing: - Fungal Skin Infection, Tinea Corporis | Not yet recruiting | Sohag University | 100 | 2026-10-01 | 2026-09-01 | |
| Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea Corporis Lactoferrin 2% Cream, Luliconazole 1% Cream, Lactoferrin-Matching Placebo Cream - Tinea Corporis | Not applicable | Recruiting | Kafrelsheikh University | 100 | 2026-09-01 | 2026-11-13 |
| A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis Intra-Lesional MMR Immunotherapy - Tinea Corporis, Tinea Cruris | Not applicable | Recruiting | Abeer Mohamed Abdelaziz Elkholy | 50 | 2025-12-09 | 2025-12-31 |
| Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis Itraconazole (200 mg), Fluconazole 150 mg - Tinea Corporis, Dermatophytosis | Phase 4 | Recruiting | Urooj Fatima | 126 | 2025-11-01 | 2026-01-15 |
| Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists AI-based medical device for aided diagnosis in Dermatology - Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP) | Completed | AI Labs Group S.L | 15 | 2024-06-01 | 2026-02-24 | |
| Efficacy and Safety of Terbinafine and Itraconazole Terbinafine Tablets, Itraconazole - Tinea Corporis, Tinea Cruris | Phase 2 / Phase 3 | Unknown | Dhaka Medical College | 150 | 2023-05-01 | 2023-05-31 |
| Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis Luliconazole Cream 1%, Vehicle Cream - Tinea Corporis | Phase 4 | Completed | Bausch Health Americas, Inc. | 75 | 2016-02-08 | 2019-11-27 |
| Pediatric Subjects With Tinea Corporis Naftin Cream, Placebo Cream - Tinea Corporis | Phase 4 | Completed | Merz North America, Inc. | 230 | 2014-08-01 | 2016-10-28 |
| An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Naftin® Cream, 2% (younger pediatric cohort), Naftin® Cream, 2% (older pediatric cohort) - Tinea Corporis | Phase 4 | Completed | Merz North America, Inc. | 27 | 2014-01-01 | 2016-10-28 |
| Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Clotrimazole - Fungal Infections, Tinea Pedis | Phase 3 | Unknown | Laboratório Teuto Brasileiro S/A | 90 | 2012-04-01 | 2012-04-12 |
| Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Product 33525 - Tinea Pedis, Tinea Cruris | Phase 3 | Completed | Tinea Pharmaceuticals | 604 | 2011-05-01 | 2013-01-23 |
Tinea (14) · Tinea Cruris (6) · Tinea Pedis (3) · Acne Conglobata (1) · Acne Vulgaris (1) · Acute Generalized Exanthematous Pustulosis (1) · Dermatitis, Seborrheic (1) · Dermatomycoses (1) · Hidradenitis Suppurativa (1) · Impetigo (1) · Keratosis, Seborrheic (1) · Mycoses (1) · Onychomycosis (1) · Pemphigus (1) · Psoriasis (1)
Bacterial Infections and Mycoses (14) · Infections (14) · Skin Diseases, Infectious (14) · Skin and Connective Tissue Diseases (14) · Dermatomycoses (13) · Mycoses (13) · Skin Diseases (13) · Dermatitis (7) · Skin Diseases, Eczematous (7) · Intertrigo (6) · Pathological Conditions, Signs and Symptoms (4) · Foot Dermatoses (3) · Foot Diseases (3) · Pruritus (3) · Signs and Symptoms (3)
Itraconazole (4) · Clotrimazole (1) · Fluconazole (1) · Isotretinoin (1) · Lactoferrin (1) · Measles-Mumps-Rubella Vaccine (1) · Terbinafine (1) · luliconazole (1)
Merz North America, Inc. (2) · AI Labs Group S.L (1) · Abeer Mohamed Abdelaziz Elkholy (1) · Bausch Health Americas, Inc. (1) · Dhaka Medical College (1) · Dr. Amara Safdar (1) · Kafrelsheikh University (1) · Laboratório Teuto Brasileiro S/A (1) · Pak Emirates Military Hospital (1) · Sohag University (1) · Tinea Pharmaceuticals (1) · University of Faisalabad (1) · Urooj Fatima (1)
Honduras (4) · Pakistan (4) · Dominican Republic (3) · Egypt (3) · United States (3) · Puerto Rico (2) · Belize (1) · Brazil (1) · El Salvador (1) · Panama (1) · Spain (1)
Alan B. Fleischer, MD (1) · Alan Fleischer, MD (1) · Antonio Martorell, PhD (1) · Anya Loncaric (1) · Kalsoom Jawaid, MBBS, FCPS, CMT (1) · Urooj Fatima, MBBS (1)